K-bio, R&D global competitiveness will be put to the test
By Son, Hyung-Min | translator Kim, Jung-Ju
24.03.19 05:50:40
가나다라
0
The American Association for Cancer Research annual meeting (AACR 2024) will be held April 5-10
Yuhan, Hanmi Pharmaceutical, and ABL Bio will introduce their candidate bispecific antibodies for cancer immunotherapy
LegoChem Biosciences will showcase the preclinical results of ADC bispecific antibodies
▲The American Association for Cancer Research annual meeting (AACR 2024) will be held April 5-10 in San Diego.
The Korean pharmaceutical industry will showcase its new candidate products entering late-stage clinical trials or aiming to export technology on platforms, testing their global competitiveness. The spotlight is on these new candidate products, particularly the trending bispecific antibodies and antibody-drug conjugate (ADC), to identify which ones stand out from the rest. Yuhan, Hanmi Pharmaceutical, ABL Bio, and LegoChem Biosciences announced they are prepared to present the clinical trial results at the conference.
According to industry sources on the 19th, the American Association for Cancer Research annual meeting 2024 (AACR 2024) will be held April 5-10 in San Diego, United States. The AA
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)